SCHEMBL23219080

SCHEMBL23219080

COC(=O)Cc1cccc(C(N)=O)c1OCc1coc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
HTT P42858 2/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM4E B2RXH2 2/20 0.37
TP53 P04637 2/20 0.37
HSD17B10 Q99714 1/20 0.37
MTNR1B P49286 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 2/20 0.35
THRB P10828 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTR1A P08908 2/20 0.35
HTR1D P28221 2/20 0.35
HTR2C P28335 2/20 0.35
PARP15 Q460N3 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852699 1.00 MAOA (0.40) MAOAMAOBHTTALDH1A1KDM4E
SCHEMBL23218939 0.91 NPC1 (0.36) MAOAMAOBHTTALDH1A1TP53
SCHEMBL29852597 0.91 NPC1 (0.36) MAOAMAOBHTTALDH1A1TP53
SCHEMBL29852883 0.84 MAOB (0.38) MAOAMAOBHTTALDH1A1KDM4E
SCHEMBL23218869 0.84 MAOB (0.38) MAOAMAOBHTTALDH1A1KDM4E
SCHEMBL23218403 0.84 CFD (0.45) MAOAMAOBTP53MTNR1BMAPT
SCHEMBL29852668 0.84 CFD (0.45) MAOAMAOBTP53MTNR1BMAPT
SCHEMBL23218128 0.82 MAOB (0.40) MAOAMAOBALDH1A1TP53MEN1
SCHEMBL29852861 0.82 MAOB (0.40) MAOAMAOBALDH1A1TP53MEN1
SCHEMBL23218492 0.79 MEN1 (0.37) MAOAMAOBHTTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOA 1416/4885MAOB 1035/4885HTT 2238/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOA 795/4885MAOB 453/4885HTT 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.